Special Issue "Enhancing Cancer Immunotherapies by Engaging NK Cells"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: 31 December 2022 | Viewed by 67

Special Issue Editor

Dr. Matthew Blunt
E-Mail Website
Guest Editor
Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK
Interests: the interaction between NK cells and cancer; the development of novel cancer immunotherapeutic strategies

Special Issue Information

Dear Colleagues,

Immunotherapy has revolutionised the treatment landscape for human cancers; however, the focus has largely been on improving T cell function. The tumour microenvironment contains a variety of effector cell populations, and the co-ordinated activation of these is required for improved tumour control. Natural killer (NK) cells are critical effector cells which mediate anti-tumour immunity via direct cytotoxicity, antibody dependent cellular cytotoxicity and promotion of adaptive immune responses. Strategies to enhance NK cell function are at the cutting edge of translational cancer research, and current approaches include natural killer cell engagers, CAR-NK cells, cytokine mediated NK cell stimulation and checkpoint blockade. 

We are pleased to invite you to submit an original research article or review to this Special Issue of Vaccines entitled ‘Enhancing Cancer Immunotherapies by Engaging NK Cells’. This issue will cover all aspects relevant to NK cells and cancer immunotherapy.

We look forward to receiving your contributions.

Dr. Matthew Blunt
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • NK cells
  • ADCC
  • immunotherapy
  • checkpoint inhibitors
  • natural killer cell engagers
  • cytokines
  • tumour infiltration
  • vaccines

Published Papers

This special issue is now open for submission.
Back to TopTop